Johnson & Johnson says ICOTYDE sustains psoriasis skin clearance through 2 years in Phase 3 ICONIC-TOTAL study
JNJ•Johnson & Johnson disclosed two-year Phase 3 ICONIC-TOTAL results showing ICOTYDE sustained skin clearance in high-impact plaque psoriasis. Safety remained consistent with prior findings, with no new issues flagged.
1. Two-year study results
Johnson & Johnson disclosed new two-year Phase 3 ICONIC-TOTAL results for ICOTYDE (icotrokinra) in high-impact plaque psoriasis. The data showed durable skin clearance in difficult-to-treat areas, supporting the drug’s positioning as a first-line systemic therapy.
2. Safety findings
Safety remained consistent with prior findings, with no new issues flagged over the two-year follow-up. The results were previously presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress 2026.
